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Summary
 
The T cell antigen receptor (TCR) mediates recognition of peptide antigens bound in the
groove of major histocompatibility complex (MHC) molecules. This dual recognition is medi-
ated by the complementarity-determining residue (CDR) loops of the 
 
a
 
 and 
 
b
 
 chains of a sin-
gle TCR which contact exposed residues of the peptide antigen and amino acids along the
MHC 
 
a
 
 helices. The recent description of T cells that recognize hydrophobic microbial lipid
antigens has challenged immunologists to explain, in molecular terms, the nature of this inter-
action. Structural studies on the murine CD1d1 molecule revealed an electrostatically neutral
putative antigen-binding groove beneath the CD1 
 
a
 
 helices. Here, we demonstrate that 
 
a
 
/
 
b
 
TCRs, when transferred into TCR-deficient recipient cells, confer specificity for both the for-
eign lipid antigen and CD1 isoform. Sequence analysis of a panel of CD1-restricted, lipid-spe-
cific TCRs reveals the incorporation of template-independent N nucleotides that encode di-
verse sequences and frequent charged basic residues at the V(D)J junctions. These sequences
permit a model for recognition in which the TCR CDR3 loops containing charged residues
project between the CD1 
 
a
 
 helices, contacting the lipid antigen hydrophilic head moieties as
well as adjacent CD1 residues in a manner that explains antigen specificity and CD1 restriction.
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A
 
central event in the recognition of microbial patho-
gens is the interaction of specific TCRs with their
ligands (1–3). In most cases, these ligands are perceived to
be complexes between MHC molecules and peptide anti-
gens. Recently, we identified human 
 
a
 
/
 
b
 
 T cells that re-
spond to lipid and glycolipid antigens from mycobacteria
and that are restricted by CD1a, b, or c. These three CD1
isoforms are distantly related to MHC molecules and are
expressed on professional APCs, including B cells, mac-
rophages, and dendritic cells, as well as transiently on thy-
mocytes during development (4–8). The expression of
CD1a, b, and c on APCs and the bacterial origin of the
lipid antigens they present suggest a role for lipid-specific,
CD1-restricted T cells in host defense.
The appreciation that human T cells can detect lipid an-
tigens and be restricted by molecules other than those en-
coded in the MHC raises fundamental questions about how
nonpeptide antigens and CD1 molecules are recognized.
The atomic structure of mouse CD1d1 resembles class I
MHC molecules in overall topography, but in place of the
peptide-binding groove of MHC, CD1d1 possesses an an-
tigen-binding super domain composed of a hydrophobic
and nonpolar cavity potentially capable of binding the acyl
chains of lipid antigens (9). This finding suggests that CD1
molecules may have evolved to function as lipid-binding
antigen-presenting molecules. In support of this hypothesis,
recent data demonstrate a direct interaction between puri-
fied glycolipid antigens and CD1b (10) and indicate that
glycosylphosphatidylinositol is a self lipid bound by murine
CD1d1 (11).
The recognition of human CD1d and mouse CD1d1 has
been linked to a population of T cells expressing an invari-
ant, germline-encoded V
 
a
 
24-J
 
a
 
18 TCR 
 
a
 
 chain paired
primarily with V
 
b
 
11 TCR 
 
b
 
 chains (12, 13). T cells bear-
ing the invariant V
 
a
 
24-J
 
a
 
18 TCR 
 
a
 
 chain are stimulated
by CD1d
 
1
 
 APCs, suggesting that the TCR on these cells
may interact directly with CD1d, or with CD1d contain-
ing bound self-lipids. In contrast to CD1d-restricted T
cells, which respond to APCs in the absence of a foreign
antigen, the CD1a-, b-, and c-restricted T cells examined
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in this report only respond in the presence of foreign my-
cobacterial lipid antigens. Nothing is known about the
TCRs that recognize CD1a-, b-, and c-restricted foreign
lipid antigens. Thus far, it has not been possible to visualize
the molecular basis for recognition of long chain mycolic
acids and glycolipids like lipoarbinomannan. No data are
available as to whether only invariant TCRs recognize
these foreign lipid antigens and no model has been pro-
posed for how the TCR might interact with an amphi-
pathic lipid antigen–CD1 complex.
To address these questions, we have cloned the TCRs
from a panel of CD1a-, b-, or c-restricted, lipid antigen–
specific T cells. By gene transfer, we demonstrate that the
TCR confers specificity for both foreign lipid antigen and
CD1 isoform. Sequence analyses revealed notable diversity
in TCR gene segment usage, indicating that invariant
TCRs that recognize CD1d are not predictive of the
TCRs against microbial lipid antigens. Importantly, fre-
quent usage of basic amino acids in the complementarity-
determining residue (CDR)3
 
1
 
 regions suggests a model for
the interaction of 
 
ab
 
 TCR with lipid–CD1 complexes in
which these TCR loops project directly between the CD1
 
a
 
 helices and mediate electrostatic interactions with the
polar functions of amphipathic lipid and glycolipid
antigens.
 
Materials and Methods
 
Cell Lines and mAbs.
 
The T cell lines used in this study,
DN1, CD8-1, CD8-2, DN.POTT, and LDN5, have been de-
scribed previously (4, 6, 14). T cells were cultured in 24-well
Linbro
 
®
 
 tissue culture plates (ICN Biomedicals, Inc.) in RPMI
1640 supplemented with 10% FCS, Hepes, 
 
l
 
-glutamine, essential
and nonessential amino acids, sodium pyruvate, beta-mercapto-
ethanol, and penicillin/streptomycin (complete medium) and
containing 1.5 nM recombinant human IL-2 (rhIL-2) (Ajino-
moto Co.). T cell lines were restimulated every 2 wk with CD1
 
1
 
monocytes and a chloroform/methanol extract of 
 
Mycobacterium
tuberculosis
 
 H37Ra (prepared from a 200 mg dry bacteria/ml sus-
pension; Difco Laboratories) at a 1:5,000 dilution. CD1
 
1
 
 mono-
cytes were prepared as described previously (15). In brief, adher-
ent cells from random donor Leukopacks were cultured for 3 d in
complete medium containing 300 U/ml GM-CSF (Immunex
Corp.) and 200 U/ml IL-4 (gift of Schering Corp.). J.RT3-T3.5
cells, derivatives of Jurkat cells that have defective endogenous
TCR 
 
b
 
 chain expression, were obtained from the American
Type Culture Collection and were cultured in complete medium
supplemented with G418 (1 mg/ml; GIBCO-BRL) and Hygro-
mycin B (0.5 mg/ml; GIBCO-BRL) for selection of transfec-
tants. IL-2–dependent HT-2 cells were obtained from the Amer-
ican Type Culture Collection and were cultured in complete
medium supplemented with 2 nM rhIL-2. The following puri-
fied mAbs were used: P3 (nonbinding control, mouse IgG1) (16),
10H3.9.3 (anti-CD1a, mouse IgG2a) (17), BCD1b3.1 (anti-
CD1b, mouse IgG1) (18), F10/21A3.1 (anti-CD1c, mouse IgG1;
Porcelli, S.A., unpublished results), and SPVT3b (anti-CD3
 
e
 
,
mouse IgG2a) (19).
 
Preparation of Lipid Antigens.
 
The lipids recognized by the
CD8-1 and CD8-2 T cell lines were partially purified as follows.
 
M. tuberculosis
 
 H37Ra (Difco Laboratories) was sonicated in PBS
and extracted with chloroform/methanol in a 2:1 ratio. The or-
ganic phase was recovered, dried by rotary evaporation, and re-
suspended in chloroform. The organic extract was then fraction-
ated using silica gel chromatography. The organic extract
equivalent of 10 mg dry bacteria was loaded in chloroform onto a
1 g silica gel (Selecto Scientific) column. The column was then
eluted with a step gradient of methanol in chloroform from 0 to
100% methanol in 10% increments. The lipid(s) recognized by
CD8-1 were found to fractionate predominantly in the 60:40
chloroform/methanol fraction and the lipid(s) recognized by
CD8-2 were found predominantly in the 90:10 chloroform/
methanol fraction (hereafter referred to as silica fraction 60:40
and silica fraction 90:10, respectively; reference 19a).
To isolate mycolic acids from 
 
M. tuberculosis
 
 H37Ra, dry bac-
teria were suspended in chloroform/methanol in a 2:1 ratio to
extract the majority of the lipids from the cell wall. The delipid-
ated cell walls were pelleted and dried. The pellet was saponified
with a methanol/potassium hydroxide solution to release mycolic
acids, which were then extracted with hexane. Mycolic acids
were then precipitated with ether/ethanol and dissolved in chlo-
roform. The presence of alpha, methoxy, and keto mycolic acids
was confirmed by thin-layer chromatography (data not shown).
 
T Cell Cloning.
 
T cell clones were isolated from cell lines by
limiting dilution. T cells were plated at 0.3, 1, or 5 cells/well in
96-well round-bottomed microtiter plates. Normal human PBMC
(10
 
5
 
/well) and a 1:1 mixture of two EBV-transformed human B
cell lines (5 
 
3
 
 10
 
4
 
/well) were irradiated (5,000 rad) and added as
feeder cells. PHA-P (Difco Laboratories) was added to a final con-
centration of 1:4,000 in a total volume of 150 
 
m
 
l/well in complete
medium containing 1.5 nM rhIL-2. Plates were fed after 7 d of
culture at 37
 
8
 
C and then every 3–4 d thereafter. Clones were ex-
panded by restimulation with PHA and feeder cells every 2–3 wk.
 
T Cell Proliferation Assays.
 
T cells (5–50 
 
3
 
 10
 
3
 
/well) were
cultured in triplicate in 96-well flat-bottomed microtiter plates
with or without irradiated (5,000 rad) CD1
 
1
 
 monocytes (5 
 
3
 
10
 
4
 
/well) in the presence or absence of antigen. To assess CD1
restriction, purified mAbs specific for CD1a, b, or c were added
at a final concentration of 20 
 
m
 
g/ml. Cells were cultured for 3 d
at 37
 
8
 
C, pulsed with [
 
3
 
H]thymidine (1 
 
m
 
Ci/well, 6.7 Ci/mmol,
New England Nuclear) and incubated for 5–6 h. The plates were
harvested on a Tomtec 96-well plate harvester (Wallac, Inc.) and
thymidine incorporation was measured with a Betaplate liquid
scintillation counter (Wallac Inc.).
 
Inverse PCR.
 
Inverse PCR was used to determine the TCR
 
a
 
 and 
 
b
 
 gene usage as described previously (20, 21). In brief, total
RNA was isolated from 2 
 
3
 
 10
 
5
 
–2 
 
3
 
 10
 
6
 
 T cells mixed with 10
 
6
 
EBV-transformed B cell line DG-EBV as carrier using guanidin-
ium thiocyanate (22). Oligo(dT)-primed double-stranded cDNA
was synthesized from total RNA, and incubated with T4 DNA
polymerase to form blunt-ended cDNA. The blunt-ended
cDNA was then circularized with T4 DNA ligase and used as a
template for PCR using a pair of C
 
a
 
- or C
 
b
 
-specific primers ori-
ented in opposite directions. The primers were C
 
a
 
-forward: 5
 
9
 
-
gggtcgacgacctcatgtctagcacagt-3
 
9
 
; C
 
a
 
-inverse: 5
 
9
 
-gcatgcggccgccctgc-
tatgctgtgtgtct-3
 
9
 
; C
 
b
 
-forward: 5
 
9
 
-gggtcgacacacagcgacctcgggtggg-3
 
9
 
;
C
 
b
 
-inverse: 5
 
9
 
-gcatgcggccgccatggtcaagagaaagga-3
 
9
 
. The amplified
TCR genes (700–800 bp in length) that include V(D)J sequences
were cloned into pBluescript II (Stratagene) and sequenced using
 
1
 
Abbreviations used in this paper:
 
 CDR, complementarity-determining resi-
dues; rhIL-2, recombinant human IL-2; UTR, untranslated region.
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the Sequenase v. 2.0 sequencing kit (United States Biochemical)
according to the manufacturer’s instructions.
 
TCR Cloning.
 
To isolate full-length cDNAs encoding the
TCRs, we designed V
 
a
 
- and V
 
b
 
-specific primers for the appropri-
ate V genes identified by sequence analysis of inverse PCR products.
The following primers were used: BV5S1: 5
 
9
 
-gggctcgagccctgagcaca-
gacacagtg-3
 
9
 
; BV2S1: 5
 
9
 
-gggctcgagaaggtggtgtgaggccat-3
 
9
 
; BV9S1:
5
 
9
 
-gggctcgagctgcagaccagaatcctgccc-3
 
9
 
; CBETA2: 5
 
9
 
-gggggatcctggg-
tgaggatgaagaatg-3
 
9
 
; AV8S2: 5
 
9
 
-gggctcgagtatgactgatcctatttggg-3
 
9
 
;
AV1S3: 5
 
9
 
-ggggtaccagctcaaggtcctgca-3
 
9
 
; AV16S1: 5
 
9
 
-gggctcgag-
cttagctggagccatggc-3
 
9
 
; CALPHA: 5
 
9
 
-gggggatccaggctgtcttacaatct-
tgca-3
 
9
 
. RNA isolated from T cell clones or lines was used to
synthesize single-stranded cDNA with Superscript II reverse tran-
scriptase (GIBCO-BRL) and an oligo(dT) primer. This cDNA
was used as a template for PCR with the appropriate primers us-
ing the following reaction conditions: 95
 
8
 
C, 30 s; 52
 
8
 
C, 1 min;
72
 
8
 
C, 1 min; 30 cycles. PCR products were digested with appro-
priate restriction endonucleases, gel purified, and ligated into
pREP7 (TCR 
 
a
 
 chains) or pREP9 (TCR 
 
b
 
 chains) (Invitrogen).
 
TCR Transfection.
 
a
 
/
 
b
 
 TCR transfectants of J.RT3-T3.5
cells were produced as described (23). J.RT3-T3.5 cells were pel-
leted and resuspended at 4 
 
3
 
 10
 
7
 
/ml in complete medium, and
0.3 ml of cells was aliquoted to each electroporation cuvette. 20 
 
m
 
g
of each plasmid (pREP7-TCR-
 
a
 
 and REP9-TCR-
 
b
 
) was added
to the cells and incubated at room temperature for 10 min. The
cells were electroporated (960 
 
mF, 250 V) with a Gene Pulser
(Bio-Rad Laboratories, Inc.) and incubated at room temperature
for an additional 10 min. The transfectants were cultured for 48 h
at 378C in complete medium and then transferred to medium
containing G418 (1 mg/ml) and Hygromycin B (0.5 mg/ml). Af-
ter 2–4 wk of culture, transfectants were analyzed by flow cytom-
etry and used in T cell transfectant stimulation assays.
Flow Cytometry. Transfectants were analyzed for cell surface
expression of TCR–CD3 complexes as follows. Cells were incu-
bated for 45 min on ice in the presence of 20 mg/ml SPVT3b
(anti-CD3e) or control antibodies in 50 ml PBS/5% FCS at 106
cells/ml. The cells were washed with PBS/FCS and resuspended
in 20 mg/ml FITC-goat F(ab9)2 anti–mouse IgG/IgM (Biosource
International) in 50 ml PBS/FCS at 106 cells/ml and incubated
for 45 min on ice. Cells were washed, resuspended in PBS/FCS
and analyzed on a FACSORT® flow cytometer (Becton Dickin-
son and Co.). Dead cells were excluded based on forward and
side scatter.
T Cell Transfectant Stimulation Assay. J.RT3-T3.5/TCR-a/b
transfectants (105/well) were cultured in 96-well flat-bottomed
microtiter plates either in the presence of 10 ng/ml PMA alone,
or in the presence of PMA plus CD11 APCs with or without dif-
ferent lipid antigens (mycolic acids isolated from M. tuberculosis
H37Ra or silica column fractions of an organic extract of M. tu-
berculosis H37Ra). Human PB CD11 monocytes (5 3 104/well)
were used as APCs with or without the following mAbs (at a
concentration of 20 mg/ml): P3 (isotype control), 10H3.9.3
(anti-CD1a), BCD1b3.1 (anti-CD1b), or F10/21A3.1 (anti-
CD1c). Cultures were set up in a total volume of 200 ml/well in
triplicate. 25-ml aliquots of the culture supernatants were col-
lected after 20–24 h and diluted 1:4 with culture medium. To
measure the amount of IL-2 released into the supernatants, HT-2
cells (5,000/well) were added and cultured for 25–30 h.
[3H]Thymidine (1 mCi/well, 6.7 Ci/mmol) was added during
the final 5–6 h of culture. [3H]Thymidine incorporation was
measured with a liquid scintillation counter.
TCR–CD1b Modeling. Alignment of amino acid sequences
was performed using the programs PILEUP and BESTFIT, part
of the Wisconsin Package Version 9.1 (Genetics Computer
Group). The primary structure of human CD1b was aligned with
the murine CD1d1 molecule (46.9% identity). Residues differing
between proteins were mutated using the program O (24), and
the conformation for different side chains was assigned based on
the rotamer library and the main chain conformation (25). The
model was subjected to 250 steps of energy minimization as im-
plemented in the program X-PLOR (26). Three cycles carried
out after assignment of different initial velocities resulted in virtu-
ally identical models. Bad contacts between side chains were
checked manually.
The sequences of the DN1 a and b chains were individually
aligned with the corresponding chains of TCRs whose structures
were available in the Protein Data Bank (1TCR [27], 1A07 [28],
1KB5 [29], 1NFD [30], 2CKB [31]). The variable a and b do-
mains of DN1 were constructed based on the corresponding
chains of the 2C TCR in complex with the MHC molecule
H-2Kb (31). The pairing between the a and b chains was modeled
as in 2C because of the high sequence homology (43.7% identity
for the a chain, 56.8% for the b chain). The CDR3 regions were
modeled based on the loop library implemented in O. Side
chains were mutated and the model was minimized as described
above. Additionally, the TCR framework residues were re-
strained using an harmonic strength constant of 5 kcal/molÅ2,
whereas the CDR loops were allowed to move freely to explore
more conformational space.
The CD1–TCR model was constructed by superimposing the
models of CD1b and DN1 variable domains on the 2C/H-2Kb-
dEV8 complex structure (31), using the lsq_explicit option in O.
The model was manually adjusted to remove unreasonable con-
tacts, and subjected to a final minimization as described for the
DN1 TCR. The quality of the model was assessed using
PROCHECK (32). The figures were generated with MIDAS (33).
Results
Isolation of T Cell Clones and Inverse PCR Analysis. Five
lipid-specific human T cell lines have been characterized as
restricted by CD1a (CD8-2), CD1b (DN1, DN.POTT,
LDN5), and CD1c (CD8-1) (Table I) (4, 6, 14). To study
the nature of the TCR in recognition of CD1-presented
lipid antigens, several of these T cell lines were cloned by
limiting dilution, and the specificities of the T cell clones
were confirmed in proliferation assays using purified lipid/
glycolipid antigens and CD11 monocyte APCs. The CD1
restriction of these clones was confirmed by blocking pro-
liferation with mAbs specific for CD1a, b, or c. A clone
isolated from the CD8-2 T cell line (designated CD8-2.1)
proliferated when cultured with CD11 monocytes and the
lipid fraction of M. tuberculosis strain H37Ra designated sil-
ica fraction 90:10 (see Materials and Methods). Prolifera-
tion was blocked by 96% by the inclusion of the anti-CD1a
mAb 10H3.9, but not by control mAb P3, anti-CD1b
mAb BCD1b3.1, or anti-CD1c mAb F10/21A3.8 (Fig. 1
A). Similarly, clones isolated by limiting dilution from the
DN1 (designated DN1.F9, Fig. 1 B) and CD8-1 (desig-
nated CD8-1.A2.3, Fig. 1 C) T cell lines proliferated in the
presence of M. tuberculosis strain H37Ra mycolic acids or
H37Ra-derived silica fraction 60:40, respectively. Prolifer-
ation of DN1.F9 cells was blocked by 57% with anti-
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CD1b, but only by 1–24% by control or anti-CD1a or c
mAbs, whereas proliferation of CD8-1.A2.3 cells was
blocked by 88% with anti-CD1c mAb, but not by control
or anti-CD1a or b mAbs. Thus, the specificity of these T
cell clones matches that of the published parent T cell lines
shown in Table I, and, consequently, they were used as
sources of RNA for TCR molecular cloning. Repeated T
cell cloning attempts with DN.POTT and LDN5 cell lines
failed to yield clones that expanded adequately for com-
plete analysis. Consequently, RNA was extracted from
these two long-term homogeneous, but uncloned, T cell
lines for TCR analysis. The specificity of the transfectants
derived was assessed to assure that they displayed the speci-
ficity of the parental cell lines, indicating that the correct
antigen-specific TCR a and b chain pairs had been iso-
lated.
To identify the TCR gene usage of these T cell lines and
clones, we used inverse PCR analysis, which allows clon-
ing of any TCR without prior knowledge of V or J gene
segment usage. Double-stranded cDNA was synthesized
from total cellular RNA and circularized by blunt-ended
ligation. The circular cDNAs were then used as templates
in PCR reactions with pairs of Ca- or Cb-specific primers
oriented in opposite directions. The resulting amplicons
thus included the TCR V, N/D/N, and J regions of the
TCR genes, which allowed the identification of TCR
gene segment usage. The inverse PCR products obtained
from the CD1-restricted T cell cDNAs were of the ex-
pected size (z700 bp), and these products were cloned into
pBluescript II and sequenced.
Reconstitution of TCR Expression. Although a/b TCRs
clearly interact with peptide–MHC complexes, it is not
known what role the TCR plays in the recognition of lipid
antigens and CD1 molecules. To test whether a/b TCRs
mediate lipid antigen–specific, CD1-restricted recogni-
tion, we cloned full-length cDNAs encoding the TCR a
and b chains from the DN1.F9, CD8-1.A2.3, and CD8-
2.1 T cell clones. The TCR gene segment usage identified
by inverse PCR analysis allowed design of V gene–specific
59 untranslated region (UTR) primers for the appropriate
Va and Vb genes, identified for each clone, together with
Ca or Cb 39 UTR primers. The TCR-a and TCR-b
cDNA PCR products were cloned into the pREP7 (a
chains) and pREP9 (b chains) episomal mammalian expres-
sion vectors. TCR-b–deficient Jurkat T cells (J.RT3-T3.5)
were cotransfected with the TCR-a and TCR-b cDNAs
from DN1, CD8-1, or CD8-2, and selected for 3–4 wk in
medium supplemented with G418 and Hygromycin B,
yielding transfectant cell lines designated DN1/J.RT3,
CD8-1/J.RT3, and CD8-2/J.RT3, respectively. Flow cy-
tometric analysis of the resulting T cell transfectant lines
Table I. Specificity of T Cell Lines Analyzed
T cell line Restriction element Antigen specificity
CD8-1 CD1c Phospholipid
CD8-2 CD1a Lipid
DN1 CD1b Mycolic acid
DN.POTT CD1b Mycolic acid
LDN5 CD1b Glucose monomycolate
CD8-1 and CD8-2 have specificity for two different lipid antigens
present in M. tuberculosis H37Ra extracts. Both antigens are extracted
from M. tuberculosis in chloroform/methanol (2:1), and can be resolved
by step gradient silica chromatography into fractions eluting in 60:40
(chloroform/methanol) (CD8-1) and 90:10 (chloroform/methanol)
(CD8-2). Preliminary characterization of the CD8-1 antigen shows that
it is likely to be a phospholipid (Moody, D.B., W. Muchlecker, and
S.A. Porcelli, unpublished observations).
Figure 1. Specificity of T cell clones isolated from the CD8-2, DN1,
and CD8-1 lines. CD8-2.1 (A), DN1.F9 (B), or CD8-1.A2.3 (C) T cells
(5 3 104/well) were cultured with CD11 monocytes (5 3 104/well) with
or without antigen (silica fraction 90:10 at 2 mg/ml [A], mycolic acid at
40 mg/ml [B], or silica fraction 60:40 at 5 mg/ml [C]) for 72 h. The fol-
lowing mAbs were added at a final concentration of 20 mg/ml: P3 (IgG
control), 10H3.9.3 (aCD1a), BCD1b3.1 (aCD1b), or F10/21A3.8
(aCD1c). [3H]Thymidine was added during the final 6 h of culture, after
which the plates were harvested and [3H]thymidine incorporation mea-
sured in a liquid scintillation counter. Results are expressed as mean cpm 6
SD of triplicate cultures (A and B). In C, results are from an experiment
in which short-term clones were screened in singlicate. The pattern of
antigen/CD1 recognition observed for these clones matches numerous
experiments performed with the T cell lines.
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showed that DN1/J.RT3 was 48% CD31 (with an MFI of
180), CD8-1/J.RT3 was 80% CD31 (with an MFI of 264),
and CD8-2/J.RT3 was 60% CD31 (with an MFI of 219),
whereas mock-transfected J.RT3-T3.5 cells were essen-
tially CD32 (6% positive with an MFI of 60) (Fig. 2, A–D),
indicating that transfected TCR genes were successfully
expressed in association with endogenous CD3.
TCR Transfectants Display Lipid Antigen Specificity. To
test the TCR transfectants for recognition of lipid/gly-
colipid antigens and CD1, DN1/J.RT3, CD8-1/J.RT3,
and CD8-2/J.RT3, cells were cultured with CD11 mono-
cytes and lipid antigens and IL-2 production was measured
as an index of antigen-specific activation. CD8-2/J.RT3
cells produced IL-2 in a dose-dependent manner when cul-
tured with the appropriate lipid fraction of M. tuberculosis
H37Ra (silica fraction 90:10; see Materials and Methods),
but not with other lipid preparations that did not contain
the specific antigen recognized by CD8-2 (silica fraction
60:40 or purified mycolic acids) (Fig. 3 top). In contrast,
DN1/J.RT3 and CD8-1/J.RT3 cells were specifically acti-
vated to secrete IL-2 only in the presence of purified M. tu-
berculosis mycolic acids or silica fraction 60:40, respectively
(Fig. 3, middle and bottom). Thus, the lipid antigen speci-
ficity of these TCR transfectants matched precisely the an-
tigen specificities of the original T cell lines. The sensitivity
of the DN1/J.RT3 cells for antigen was z50-fold lower
than the sensitivities of CD8-1/J.RT3 and CD8-2/J.RT3
cells for their respective antigens. It is not clear if this dif-
ference reflects variability in TCR expression levels, anti-
gen uptake or loading efficiency, affinity of the TCR for
different ligands, or some other parameter.
Similarly, full-length TCR-a and TCR-b cDNAs were
cloned from the LDN5 cell line using the sequence infor-
mation obtained by inverse PCR analysis. Transfection of
the LDN5 ab TCR into J.RT3-T3.5 cells conferred the
ability to respond to purified Mycobacterium phlei glucose
monomycolate but not to other lipid or glycolipid antigens
(data not shown). Although the TCR from DN.POTT
was not reconstituted in J.RT3-T3.5 cells, 6/6 inverse
PCR products representing in-frame TCR-a and 6/6
PCR products representing in-frame TCR-b transcripts
were identical in sequence to those shown in Table II, sug-
gesting that the DN.POTT T cell line is essentially clonal
and providing primary sequence data on its TCR (data not
shown).
Figure 2. Expression of TCR–
CD3 complex by J.RT3-T3.5
transfectants. J.RT3-T3.5 cells
were transfected with CD8-2 (B),
DN1 (C), or CD8-1 (D) a/b
TCR cDNAs in pREP7 (a
chains) and pREP9 (b chains) ex-
pression vectors or with vectors
alone (A) and selected in medium
containing G418 (1 mg/ml) and
Hygromycin B (0.5 mg/ml) for
3–4 wk. Transfectant lines were
labeled with the anti-CD3 mAb
SPVT3b (solid line) or with con-
trol mouse IgG (broken line) fol-
lowed by FITC goat anti–mouse
Ig (Fab9)2 and analyzed on a flow
cytometer.
Figure 3. Lipid antigen specificity of J.RT3/a/b TCR transfectants.
CD8-2/J.RT3 (top), DN1/J.RT3 (middle), or CD8-1/J.RT3 (bottom)
transfectants (105/well) were cultured in triplicate for 24 h in the presence
of PMA (10 ng/ml) and CD11 monocytes (5 3 104/well) with no anti-
gen (asterisk), or with a titration of M. tuberculosis H37Ra mycolic acids
(j), silica fraction 60:40 (n), or silica fraction 90:10 (d). To measure IL-2
production by the transfectants, an aliquot of the supernatants was re-
moved and diluted 1:4 with medium. HT-2 cells (5 3 103/well) were
added to the supernatants and cultured for 16–24 h. [3H]Thymidine was
added during the final 5–6 h culture, after which the plates were har-
vested and [3H]thymidine incorporation measured with a liquid scintilla-
tion counter. Results are expressed as the mean cpm 6 SD of triplicate
cultures.
200 Recognition of Lipid Antigens by T Cells
Since J.RT3-T3.5 cells express an endogenous TCR a
chain with which the transfected TCR b chains could po-
tentially form a second functional heterodimer, we made
control J.RT3 cells transfected with only the TCR b
chains of each of the TCRs studied. Although TCR b
transfectants typically expressed levels of TCR at the cell
surface similar to TCR-a/b transfectants and could be
stimulated with anti-CD3, no stimulation of IL-2 produc-
tion in response to CD11 APCs with or without lipid anti-
gens was observed (data not shown). Thus, both TCR a
and b chains from the lipid/CD1-specific T cell lines were
required to reconstitute a TCR capable of lipid-specific
recognition.
TCR Transfectants Display Specific CD1 Isoform Restriction.
The CD1 dependence of the activation of the transfectants
was determined using blocking mAbs specific for CD1a, b, or
c. IL-2 production by CD8-2/J.RT3 transfectant cells was
blocked by 95% with mAb 10H3.9.3 (anti-CD1a), but was
slightly increased by mAbs BCD1b3.1 (anti-CD1b) and F10/
21A3.1 (anti-CD1c). Similarly, the activation of DN1/J.RT3
and CD8-1/J.RT3 transfectants was specifically blocked by
anti-CD1b and anti-CD1c, respectively, but not by mAbs to
the other two CD1 isoforms tested (Fig. 4, A–C). Therefore,
reconstitution of the TCRs from three different CD1-
restricted T cells in TCR-deficient J.RT3-T3.5 cells confers
recognition of both the specific antigens and the particular
CD1 isoforms the original T cells were defined to recognize.
These results support a model in which the TCR interacts
with both lipid/glycolipid antigen and CD1 analogous to
conventional TCR–MHC–peptide interactions.
Analysis of TCR Sequences. Having confirmed that a/b
TCRs mediate lipid-specific, CD1-restricted recognition,
and having defined that the specific TCR a/b pairs cloned
from a panel of T cell lines were the correct ones for recog-
nition, we next analyzed the TCR sequences to gain in-
sight into the nature of TCR diversity for lipid-specific and
CD1-restricted T cells. The DNA sequences were aligned
with known TCR V and J segments using BLAST homol-
ogy searches (34). Two of the TCRs, those from CD8-2
and DN.POTT, expressed the AV16S1 gene, and the
other TCRs contained three different Va genes, AV1S3,
AV8S2, and AV3S1 (Table II). Five different Ja segments
were detected in the TCRs from these cells (AJ17, AJ34,
AJ31, AJ57, and AJ9). The TCR Vb genes were similarly
diverse, with BV2S1, BV9S1, BV6S1, BV5S1, and BV7S1
each represented once (Table II). However, significantly
less diversity was observed in Jb usage. Of the 13 functional
human Jb gene segments, only Jb segments BJ2S1 or
BJ2S7 were utilized by the 5 T cell lines. The deduced
amino acid sequences of the TCR V-N/D/N-J junctions
displayed in Table II indicate that the CDR3 regions of
these TCRs have typical lengths (9–13 residues in CDR3a
and 8–13 residues in CDR3b) and heterogeneous peptide
sequences. Together, the combinatorial diversity of TCR
Va, Ja, and Vb segment usage and the junctional diversity
of CDR3-encoded residues make it clear that, unlike the
invariant TCR-a genes of NKT cell recognition of CD1d,
those of foreign lipid–specific, CD1a-, b-, or c-restricted
TCR are diverse receptors similar to those of peptide-spe-
cific, MHC-restricted TCRs. Despite this general diversity,
Table II. TCR Gene Usage and Predicted CDR3 Region Protein Sequences
TCR-a
T cell line Gene usage Va CDR3 Ja
CD8-1 AV1S3, AJ17 ...CAV RRAAGNKLTF GGG...
CD8-2 AV16S1, AJ34 ...CAV RHNTDKLIF GTG...
DN1 AV8S2, AJ57 ...CAE PLSLPGGSEKLVF GKG...
DN.POTT AV16S1, AJ31 ...CAV RDEGWARLMF GDG...
LDN5 AV3S1, AJ9 ...CAS MYTGGFKTIF GAG...
TCR-b
T cell line Gene usage Vb CDR3 Jb
CD8-1 BV2S1, BJ2S7 ...CSA RTYPGTGFYEQYF GPG...
CD8-2 BV9S1, BJ2S1 ...CAS SSMYNEQFF GPG...
DN1 BV5S1, BJ2S7 ...CAS SLVRRYEQYF GPG...
DN.POTT BV6S1, BJ2S1 ...CAS SLTRSSHNEQFF GPG...
LDN5 BV7S1, BJ2S1 ...CAS SQPIGGGEQFF GPG...
The TCR V and J gene usage for each T cell line is indicated. The predicted amino acid sequences from the CDR3 junctional regions of each TCR
a and TCR b chain are shown with basic amino acid residues encoded by N nucleotides underscored. These sequence data are available from
EMBL/GenBank/DDBJ under accession numbers AF107998–AF108007.
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close scrutiny revealed an overrepresentation of basic resi-
dues, particularly arginine, concentrated near the NH2 ter-
minal ends of the CDR3 regions. These basic residues ap-
pear in the a chain (CD8-2), in the b chain (DN1), or in
both a and b chains (CD8-1 and DN.POTT) of the a/b
TCR pairs (Table II), suggesting an important role in the
specific recognition mediated by all of these TCRs (see be-
low).
Modeling of the TCR–CD1 Interaction. Given the over-
all structural similarity between MHC and the mouse
CD1d1 crystal structures, together with evidence for lipid
binding to human CD1b, we reasoned that lipid–CD1
complexes may form a TCR ligand analogous to peptide–
MHC. Furthermore, our analysis of CD1-restricted TCR
sequences indicates that they are comparable in primary
structure to peptide–MHC-specific TCRs, using the same
gene elements and having CDR3 lengths of comparable
size to those found in MHC-restricted TCRs. Therefore,
we modeled the DN1 TCR variable domains and human
CD1b based on the known structures of other a/b TCRs
and the mouse CD1d1 protein, respectively. We then
modeled the DN1 TCR as a complex with human CD1b
using the TCR/MHC/peptide ternary crystal structures to
orient the molecules together (Fig. 5). This model suggests
that the DN1 TCR could interact with CD1b in a manner
that is similar to that of TCRa/b with peptide–MHC
complexes. Strikingly, this would result in the positioning
of the TCR CDR3 loops over the center of the putative
CD1 antigen–binding site that is flanked by the CD1 a he-
lices. Such an orientation would allow the basic residues in
the DN1 TCR b chain CDR3 region to project into the
central region of the groove that would provide direct in-
teractions with exposed portions of a bound lipid or with
the exposed carbohydrate of bound glycolipids. In particu-
lar, if the lipid antigen hydrophobic aliphatic chains are
embedded in the electrostatically neutral CD1 pockets, the
hydrophilic end of the lipid (or glycolipid) might be lo-
cated between the CD1 a helices. This would orient the
TCR CDR3 residues to interact with segments of the
CD1 a helices and the charged CDR3 residues would
project between the CD1 a helices in position to contact
the polar head of the lipid (or glycolipid) (Fig. 5).
Discussion
That T cells bearing a/b TCR mediate lipid and gly-
colipid-specific, CD1a-, b-, or c-restricted recognition
raised questions about the role of the a/b TCR in this
process. Previously, the a/b TCR was thought to interact
solely with MHC class I or II molecules complexed with
antigenic peptides or protein superantigens. Here we have
demonstrated that the TCRs from a panel of lipid/CD1–
specific T cells mediate the ability of those T cells to dis-
criminate between foreign lipid antigens and CD1 isoforms.
The recent crystal structure of mouse CD1d1 revealed the
presence of a hydrophobic binding cavity potentially capa-
ble of accommodating the hydrophobic aliphatic portions
of a lipid antigen (35). Together with these structural data
and the recent evidence that glycolipid antigens can bind
directly to human CD1b in vitro (10), our findings suggest
that lipids and CD1 molecules form complexes analogous
to peptide–MHC complexes that are recognized together
by a single TCR.
Recognition of lipid–CD1 complexes by the a/b TCR
greatly expands the universe of foreign antigens recognized
by T cells and reveals that previous assumptions that a/b
TCRs were exclusively peptide/MHC–specific were not
entirely correct. Although the relative frequencies of CD1-
restricted versus MHC-restricted T cells are unknown, the
prominent expression of CD1a, b, and c on many profes-
sional APCs suggests that recognition of this lineage of an-
tigen-presenting molecules may be substantial. Here, the
TCRs were derived from both the major CD81 and rela-
tively minor CD42CD82 T cell pools that contain foreign
lipid/CD1–specific T cells. We have also recently demon-
strated that g/d T cells can recognize CD1c via a TCR-
Figure 4. CD1 specificity of J.RT3/a/b TCR transfectants. CD8-2/
J.RT3 (A), DN1/J.RT3 (B), or CD8-1/J.RT3 (C) transfectants (105/
well) were cultured in triplicate for 24 h in the presence of PMA (10 ng/ml)
and CD11 monocytes (5 3 104/well) with no antigen, or with 50 mg/ml
M. tuberculosis H37Ra mycolic acids (DN1/J.RT3), 1 mg/ml silica frac-
tion 60:40 (CD8-1/J.RT3), or 1 mg/ml silica fraction 90:10 (CD8-2/
J.RT3). Cultures with antigen were set up with or without the following
mAbs at a final concentration of 20 mg/ml: 10H3.9.3 (anti-CD1a),
BCD1b3.1 (anti-CD1b), or F10/21A3.8 (anti-CD1c). IL-2 production
was measured as described for Fig. 3. Results are expressed as the mean
cpm 6 SD of triplicate cultures.
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dependent mechanism (Spada, F., E.P. Grant, D. Leslie,
and M.B. Brenner, unpublished observations), indicating
the ability of both TCR types to interact with CD1.
The sequence analysis of a cross-section of CD1-
restricted T cells shows dramatic heterogeneity in Va, Vb,
and Ja gene usage among the TCRs. This diversity is in
marked contrast to human CD1d-restricted T cells, which
use an invariant germline-encoded TCR a chain composed
of a precise AV24S1-AJ18 rearrangement together with a
restricted pattern of Vb chains (36), and to murine CD1d1-
restricted NK T cells which use a similar TCR (37). These
CD1d-specific T cells recognize CD1d in the absence of
exogenously supplied lipid antigens, and it is not clear if
they respond to empty CD1d molecules or to CD1d com-
plexed to endogenous lipids/glycolipids. In the analysis pre-
sented here, three CD1b-restricted TCRs (DN1, DN.POTT,
and LDN5) are described that use three different Va and
Vb genes and have sequence diversity in both TCR-a and
-b CDR3 regions. Thus, the recognition of exogenous
lipid antigens with CD1b is more like peptide–MHC rec-
ognition than the response to CD1d. By extension, we ex-
pect that T cells specific for CD1a- and CD1c-restricted
lipids will also have significantly greater diversity than has
been observed for CD1d-specific T cells. This hypothesis is
supported by the presence of template-independent N nu-
cleotides in the TCR-a and -b sequences of CD8-2
(CD1a-restricted) and CD8-1 (CD1c-restricted) TCRs.
Despite the diversity that we observed in TCR usage,
we noted the frequent coding of basic residues in CDR3a
and CDR3b, primarily as a result of N nucleotide addi-
tions. If the hydrophobic antigen–binding pocket of CD1
binds to the hydrophobic acyl portions of a lipid antigen,
the polar phosphate, carboxylic acid, or carbohydrate re-
gions of the antigens would be exposed at the opening in
the CD1 groove between the CD1 a helices to facilitate
direct contacts with the TCR. We speculate that in the case
of the mycolic acid–specific TCRs (DN1 and DN.POTT)
the positively charged residues in the TCR CDR3 regions
are positioned to interact with negatively charged lipid
antigen head groups that would be exposed between the
CD1 a helices. It is noteworthy that the one TCR de-
scribed here that is specific for an antigen which does not
have a negatively charged head group, LDN5, lacks posi-
tively charged amino acids in the CDR3 regions. We gen-
erated a molecular model of the DN1 TCR variable do-
mains together with a model of the CD1b a1 and a2
domains based on the crystal structures of TCR–MHC–
Figure 5. Molecular model of the DN1 TCR Va/Vb domains with
the CD1b a1/a2 domains. The deduced amino acid sequences of the
DN1 TCR and human CD1b were used to create a model of the protein
structures based on the crystal structures for TCRs, mouse CD1d1, and
TCR–MHC–peptide complexes. (A) Ca backbone of the TCR variable
regions (top) complexed with the putative antigen binding region (a1 and
a2 domains) of CD1b (bottom). The TCR CDR3 regions are colored:
CDR1a, red; CDR2a, green; CDR3a, light blue; CDR1b, orange;
CDR2b, yellow; CDR3b, dark blue. (B) View of the TCR (blue) and
CD1b (red) complex, represented by the Ca backbone, looking down the
putative antigen-binding site of CD1b, flanked to the left and right by the
CD1 a2 and a1 helices, respectively. The side chains of R97 and R98 res-
idues in the DN1 TCR CDR3b, indicated in yellow, project down into
the hydrophobic cleft formed by the CD1 a helices. (C) Illustration of the
proposed interaction between charged residues in the DN1 TCR CDR3
loops and polar or charged regions of mycolic acid bound to CD1b.
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peptide complexes (27, 28) and the murine CD1d1 mole-
cule (9) in order to visualize the hypothetical mode of in-
teraction of these proteins (Fig. 5 A). This model suggests
that CD1-restricted TCRs could interact with CD1 in a
way analogous to TCR–MHC. Importantly, this model
readily positions the basic residues R97 and R98 in the
DN1 CDR3b loop in a location favorable for direct inter-
action with any moieties protruding from the CD1b hy-
drophobic pockets and positioned between the CD1 a he-
lices (Fig. 5 B). Given the likely possibility that lipid
binding to CD1 would be primarily through hydrophobic
interactions of acyl chains inside the hydrophobic cavity,
we speculate that the polar regions of the lipid antigens
would be most likely to be exposed at the opening to this
putative antigen-binding site. In the case of mycolic acid,
the most polar region of the molecule consists of a carbox-
ylic acid group and a hydroxyl group. Therefore, one or
both of the arginine residues in the DN1 CDR3b might
directly interact with this region of a bound mycolic acid
molecule, making contacts important for the specificity and
strength of the interaction between TCR and CD1–lipid,
as illustrated schematically in Fig. 5 C. Ultimately, crystallo-
graphic studies are required in order to determine whether
this model is correct and to reveal any unexpected differ-
ences between the mechanisms by which TCR interacts
with lipid–CD1 and peptide–MHC ligands.
All of the TCRs isolated in this study incorporate either
the BJ2S1 or BJ2S7 gene segments. This finding is also in
contrast to the TCR sequences reported for CD1d-reactive
T cells, which show no obvious bias in Jb segment usage.
Interestingly, the TCRs expressed by a CD1 directly reactive
jejunal IEL T cell line described by Balk et al. predominantly
used BJ2S1, and a CD1c directly reactive T cell clone iso-
lated from that line expressed BJ2S7 (38). Additionally, two
other CD1a or CD1c directly reactive T cell lines derived in
our laboratories also express BJ2S1 and BJ2S7 (Grant, E.P.,
S.A. Porcelli, and M.B. Brenner, unpublished observations).
The BJ2S1 and BJ2S7 gene products are quite similar to one
another and are distinguished from the other Jb segments by
the motif ‘EQ(Y/F)F’, which is predicted to lie near the
COOH-terminal end of the CDR3b. It is possible that this
portion of the CDR3b mediates important interactions with
CD1a, b, and c molecules themselves, accounting for their
increased incidence in the TCRs analyzed here. Alterna-
tively, these residues may be critical for the positioning of
the CDR loops such that they adopt a conformation suitable
for interaction with CD1a, b, or c.
In these analyses, we have examined the receptors from a
panel of T cells with diverse specificities for lipid antigens
and CD1 isoform restriction. Despite this diversity, we
have identified two potentially important TCR structural
features that may be involved in the interaction of these
TCRs with their lipid–CD1 ligands. We did not observe
any clear bias in V gene usage by these TCRs, which testi-
fies to the diversity of the T cell repertoire capable of inter-
acting with nonpolymorphic CD1 molecules and their
lipid antigens. Nonetheless, it is possible that a more exten-
sive analysis of T cells with specificity for a single lipid anti-
gen and with a common CD1 isoform restriction will re-
veal additional antigen-specific or CD1a-, b-, or c-specific
biases in V gene usage.
Although the CD1 family of proteins is quite divergent
from MHC at the sequence level, it is now clear that the
two types of antigen-presenting molecules have sufficient
structural similarities to allow the same set of TCR V and J
segments to be combined to form TCR heterodimers that
can interact with two extremely distinct classes of antigens.
Thus, the previous paradigm that a/b TCRs are specific
for peptide–MHC complexes must be modified. The TCR
transfer studies presented here demonstrate directly that di-
verse TCR-a/b heterodimers instead mediate the recogni-
tion of foreign lipid and glycolipid antigens in the context
of nonpolymorphic CD1a, b, and c antigen-presenting ele-
ments. Furthermore, although the CD8-1 and CD8-2 T
cell lines are CD8a/b1, reconstitution of the TCRs in the
J.RT3-T3.5 cell line, which is CD8a/b negative, confers
the ability to productively interact with CD1, indicating
that CD8 coreceptor expression is not essential to recogni-
tion of these presenting elements. These findings raise addi-
tional questions about CD1-restricted T cells, including
how they are selected during thymic development and
how a/b TCRs achieve specificity for CD1 versus MHC,
given the use of the same families of germline TCR ele-
ments. Moreover, the relative frequency of CD1 versus
MHC-reactive T cells during the course of infection and in
autoimmune responses must now be evaluated to appreci-
ate the relevance of these two antigen-presenting systems
in various host responses.
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